137 related articles for article (PubMed ID: 34989454)
1. Antibody responses to inactivated SARS-CoV-2 vaccine in peritoneal dialysis patients.
Murt A; Altiparmak MR; Ozbey D; Yalin SF; Sert Yadigar S; Karaali R; Kocazeybek B; Saltoglu N; Pekpak M; Ataman MR
Semin Dial; 2022 May; 35(3):264-268. PubMed ID: 34989454
[TBL] [Abstract][Full Text] [Related]
2. Waning of SARS-CoV-2 Vaccine-Induced Immune Response over 6 Months in Peritoneal Dialysis Patients and the Role of a Booster Dose in Maintaining Seropositivity.
Murt A; Dinc HO; Altiparmak MR; Yalin SF; Yadigar S; Parmaksiz E; Kocazeybek B; Pekpak M; Ataman MR
Nephron; 2022; 146(6):559-563. PubMed ID: 35598596
[TBL] [Abstract][Full Text] [Related]
3. Antibody responses to the SARS-CoV-2 vaccines in hemodialysis patients: Is inactivated vaccine effective?
Murt A; Altiparmak MR; Yadigar S; Yalin SF; Ozbey D; Yildiz Z; Kocazeybek B; Pekpak M; Ataman MR
Ther Apher Dial; 2022 Aug; 26(4):769-774. PubMed ID: 34741418
[TBL] [Abstract][Full Text] [Related]
4. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis.
Bensouna I; Caudwell V; Kubab S; Acquaviva S; Pardon A; Vittoz N; Bozman DF; Hanafi L; Faucon AL; Housset P
Am J Kidney Dis; 2022 Feb; 79(2):185-192.e1. PubMed ID: 34508833
[TBL] [Abstract][Full Text] [Related]
6. Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients - the Vienna Cohort.
Beilhack G; Monteforte R; Frommlet F; Gaggl M; Strassl R; Vychytil A
Front Immunol; 2021; 12():780594. PubMed ID: 34925359
[TBL] [Abstract][Full Text] [Related]
7. Local and Systemic Immunity Are Impaired in End-Stage-Renal-Disease Patients Treated With Hemodialysis, Peritoneal Dialysis and Kidney Transplant Recipients Immunized With BNT162b2 Pfizer-BioNTech SARS-CoV-2 Vaccine.
Piotrowska M; Zieliński M; Tylicki L; Biedunkiewicz B; Kubanek A; Ślizień Z; Polewska K; Tylicki P; Muchlado M; Sakowska J; Renke M; Sudoł A; Dąbrowska M; Lichodziejewska-Niemierko M; Smiatacz T; Dębska-Ślizień A; Trzonkowski P
Front Immunol; 2022; 13():832924. PubMed ID: 35935974
[TBL] [Abstract][Full Text] [Related]
8. Dialysis modality, humoral response to vaccine, and SARS-CoV-2 infection risk: Comparative prospective evaluation.
Bnaya A; Nacasch N; Einbinder Y; Shavit L; Erez D; Shashar M; Grupper A; Benchetrit S; Wand O; Cohen-Hagai K
Semin Dial; 2023; 36(5):382-389. PubMed ID: 37042666
[TBL] [Abstract][Full Text] [Related]
9. Anti-SARS-CoV-2 IgG antibody titer after BNT162b2 mRNA COVID-19 vaccination in Japanese patients who underwent renal replacement therapy, hemodialysis, peritoneal dialysis, and kidney transplantation.
Iwabuchi R; Harada M; Yamada A; Aomura D; Yamada Y; Sonoda K; Nakazawa H; Sakai K; Mizukami E; Hashimoto K; Kamijo Y
Clin Exp Nephrol; 2023 Aug; 27(8):660-671. PubMed ID: 37095343
[TBL] [Abstract][Full Text] [Related]
10. Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients.
Dheir H; Tocoglu A; Toptan H; Pinar M; Demirci T; Koroglu M; Yaylaci S; Genc AB; Genc AC; Firat N; Karabay O; Sipahi S
J Med Virol; 2022 Jul; 94(7):3176-3183. PubMed ID: 35277975
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
Front Immunol; 2021; 12():690698. PubMed ID: 34276681
[TBL] [Abstract][Full Text] [Related]
12. [Antibody Response After Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: A Prospective Observational Study].
Özgür D; Tütüncü EE
Mikrobiyol Bul; 2022 Jan; 56(1):36-48. PubMed ID: 35088958
[TBL] [Abstract][Full Text] [Related]
13. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
14. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
Front Immunol; 2021; 12():786554. PubMed ID: 35003104
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
16. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.
Zhang J; He Q; An C; Mao Q; Gao F; Bian L; Wu X; Wang Q; Liu P; Song L; Huo Y; Liu S; Yan X; Yang J; Cui B; Li C; Wang J; Liang Z; Xu M
Emerg Microbes Infect; 2021 Dec; 10(1):1598-1608. PubMed ID: 34278956
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Dynamic Humoral Response to SARS-CoV-2 mRNA Vaccines in Patients on Peritoneal Dialysis.
Quiroga B; Soler MJ; Ortiz A; Gansevoort RT; Leyva A; Rojas J; de Sequera P;
Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298603
[TBL] [Abstract][Full Text] [Related]
18. Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis.
Goupil R; Benlarbi M; Beaubien-Souligny W; Nadeau-Fredette AC; Chatterjee D; Goyette G; Gunaratnam L; Lamarche C; Tom A; Finzi A; Suri RS;
CMAJ; 2021 May; 193(22):E793-E800. PubMed ID: 33980499
[TBL] [Abstract][Full Text] [Related]
19. Impaired antibody response to inactivated COVID-19 vaccines in hospitalized patients with type 2 diabetes.
Zhou X; Lu H; Sang M; Qiu S; Yuan Y; Wu T; Chen J; Sun Z
Hum Vaccin Immunother; 2023 Dec; 19(1):2184754. PubMed ID: 36864628
[TBL] [Abstract][Full Text] [Related]
20. Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study.
Quiroga B; Soler MJ; Ortiz A; Martínez Vaquera S; Jarava Mantecón CJ; Useche G; Sánchez Márquez MG; Carnerero M; Jaldo Rodríguez MT; Muñoz Ramos P; Ruiz San Millán JC; Toapanta N; Gracia-Iguacel C; Aguilar Cervera MC; Balibrea Lara N; Leyva A; Rojas J; Gansevoort RT; de Sequera P;
Nephrol Dial Transplant; 2022 Sep; 37(10):1868-1878. PubMed ID: 34788858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
